Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimo Dietrich

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2021
DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates With HPV Status, Mutational Load, an Interferon-γ Signature, Signatures of Immune Infiltrates, and SurvivalSophia M Loick, Anne Fröhlich, Jennis Gabrielpillai, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
<i>LAG3</i> (<i>LAG-3</i>, <i>CD223</i>) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Emma Grace Bawden, et al.
Plos One|April 5, 2014
Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urineEmily Eva Holmes, Maria Jung, Sebastian Meller, et al.
Pigment Cell & Melanoma Research|November 17, 2023
CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanomaLuka de Vos-Hillebrand, Simon Fietz, Philip Hillebrand, et al.
The Journal of Molecular Diagnostics : JMD|May 4, 2020
Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood: An Observational Prospective StudyLuka de Vos, Maria Jung, Ruth-Miriam Koerber, et al.
Cancer Immunology, Immunotherapy : CII|November 16, 2020
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)Simon Fietz, Romina Zarbl, Dennis Niebel, et al.
American Journal of Translational Research|February 7, 2024
Hypermethylated SHOX2 in circulating cell-free DNA post renal cell carcinoma surgery as TNM-independent biomarker for recurrence riskThomas Büttner, Romina Zarbl, Philipp Krausewitz, et al.
The American Journal of Pathology|January 24, 2021
DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate CancerYuri Tolkach, Romina Zarbl, Simone Bauer, et al.
Plos One|November 1, 2016
DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary TractBarbara Uhl, Dimo Dietrich, Vittorio Branchi, et al.
Oncotarget|September 9, 2017
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinomaTim Müller, Martin Braun, Dimo Dietrich, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2021
DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates With HPV Status, Mutational Load, an Interferon-γ Signature, Signatures of Immune Infiltrates, and SurvivalSophia M Loick, Anne Fröhlich, Jennis Gabrielpillai, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
<i>LAG3</i> (<i>LAG-3</i>, <i>CD223</i>) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Emma Grace Bawden, et al.
Plos One|April 5, 2014
Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urineEmily Eva Holmes, Maria Jung, Sebastian Meller, et al.
Pigment Cell & Melanoma Research|November 17, 2023
CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanomaLuka de Vos-Hillebrand, Simon Fietz, Philip Hillebrand, et al.
The Journal of Molecular Diagnostics : JMD|May 4, 2020
Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood: An Observational Prospective StudyLuka de Vos, Maria Jung, Ruth-Miriam Koerber, et al.
Cancer Immunology, Immunotherapy : CII|November 16, 2020
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)Simon Fietz, Romina Zarbl, Dennis Niebel, et al.
American Journal of Translational Research|February 7, 2024
Hypermethylated SHOX2 in circulating cell-free DNA post renal cell carcinoma surgery as TNM-independent biomarker for recurrence riskThomas Büttner, Romina Zarbl, Philipp Krausewitz, et al.
The American Journal of Pathology|January 24, 2021
DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate CancerYuri Tolkach, Romina Zarbl, Simone Bauer, et al.
Plos One|November 1, 2016
DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary TractBarbara Uhl, Dimo Dietrich, Vittorio Branchi, et al.
Oncotarget|September 9, 2017
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinomaTim Müller, Martin Braun, Dimo Dietrich, et al.
Pageof 12